Skip to content

DrugShortage News & Analysis

1 article

Market Mood

0 Bullish0 Neutral1 Bearish
Sanofi (SNY) Pompe Drug Shortage Disrupts Patient Treatments Until November
EarningsBearish11/19/2026

Sanofi (SNY) Pompe Drug Shortage Disrupts Patient Treatments Until November

Sanofi (SNY) is experiencing a supply shortage of its Pompe disease treatments, Lumizyme and Nexviazyme, causing canceled infusions for some patients. The shortage stems from manufacturing issues at Sanofi's Ireland plant and shipping delays are expected to continue disrupting patient treatment through the end of November. Pompe disease is a rare genetic illness causing muscle weakness and respiratory difficulties due to an enzyme deficiency. Sanofi's enzyme replacement drugs are given every two weeks to manage symptoms. The company stated there is no issue with drug quality and is prioritizing treatment access for vulnerable patients during the shortage. The FDA has confirmed patient access to these treatments is a priority and is assisting Sanofi to ensure supply needs are met. The prolonged disruption affects patients heavily reliant on these drugs, as alternative treatments are still in clinical trials. This ongoing shortage illustrates the risks in supply chain and manufacturing for critical rare disease medications. This matters for investors because prolonged supply interruptions at Sanofi's production facility could affect sales revenue from these key rare disease drugs through at least November, given the company’s reliance on consistent drug availability for patient treatments.

Read More: Sanofi (SNY) Pompe Drug Shortage Disrupts Patient Treatments Until November